Literature DB >> 18362003

Adaptation of the OODA Loop to reduce postoperative nausea and vomiting in a high-risk outpatient oncology population.

Penelope S Villars1, Mark Q Veazie, Joel S Berger, Quan M Vu, Alita A Campbell-McAdory, John C Frenzel, Spencer S Kee.   

Abstract

Postoperative nausea and vomiting (PONV) remains a ubiquitous concern for surgical outpatients with published rates ranging from 14% to 80%. An evidence-based approach was used to reduce PONV in a high-risk adult outpatient oncology population. The Observe, Orient, Decide, and Act (OODA) Loop, a rapid cycle management strategy, was adapted for use in an outpatient surgery center with six ORs. A PONV prophylaxis protocol was developed and adapted until a stable PONV rate was achieved. A combination of dexamethasone, promethazine, and ondansetron was used in patients with one to three PONV risk factors. Patients with four major risk factors received an additional intervention. The PONV rate for the final protocol stabilized below 4% by 46 weeks and remained stable through 79 weeks. The OODA paradigm provides an effective technique for interfacing health care research with clinical practice. In this case, an effective PONV prophylaxis plan was developed from within a collaborative nursing and medical setting.

Entities:  

Mesh:

Year:  2008        PMID: 18362003     DOI: 10.1016/j.jopan.2007.11.008

Source DB:  PubMed          Journal:  J Perianesth Nurs        ISSN: 1089-9472            Impact factor:   1.084


  2 in total

1.  In thrombin stimulated human platelets Citalopram, Promethazine, Risperidone, and Ziprasidone, but not Diazepam, may exert their pharmacological effects also through intercalation in membrane phospholipids in a receptor-independent manner.

Authors:  Ramadhan Oruch; Erlend Hodneland; Ian F Pryme; Holm Holmsen
Journal:  J Chem Biol       Date:  2009-04-30

2.  Toward Medical Documentation That Enhances Situational Awareness Learning.

Authors:  Leslie A Lenert
Journal:  AMIA Annu Symp Proc       Date:  2017-02-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.